BRAF<sup>V600E</sup>突变和cN0期甲状腺乳头状癌淋巴结转移相关性研究

高庆军; 张伟; 王南鹏; 段海松; 周彦; 张薇; 赵代伟

doi:10.13201/j.issn.1001-1781.2015.23.009

BRAF^V600E突变和cN0期甲状腺乳头状癌淋巴结转移相关性研究

- 1. 贵州医科大学附属医院甲状腺外科;
- 2. 贵州医科大学第二附属医院甲状腺外科

详细信息

通讯作者: 赵代伟,E-mail:zhaodw@hotmail.com

中图分类号: R736.1

收稿日期: 2015-09-01

Study on the correlation between BRAF^V600E mutation and lymphatic metastases in papillary thyroid cancer staged preoperatively as N0

- 1 Department of Thyroid Surgery, the Affiliated Hospital of Guizhou Medical University, Guiyang, 550004, China;
- 2 Department of Thyroid Surgery, the Second Affiliated Hospital of Guizhou Medical University

More Information

Corresponding author: ZHAO Daiwei, E-mail: zhaodw@hotmail.com

Received Date: 01 September 2015

摘要

摘要: 目的: 研究BRAF^V600E基因突变在cN0期甲状腺乳头状癌(PTC)中的突变发生率,探讨BRAF^V600E突变与PTC(cN0期;肿瘤直径 ≤ 2 cm)颈部淋巴结转移的相关性。方法: 应用巢式PCR基因测序法检测72例行预防性中央区淋巴结清扫的PTC石蜡包埋组织中BRAF^V600E突变情况,结合患者临床病理资料,分析引起BRAF^V600E基因突变和PTC(cN0期)中央区淋巴结转移的相关性。结果: BRAF^V600E基因突变率为47.22%(34/72),中央区颈部淋巴结隐性转移率为36.11%(26/72)。cN0期PTC淋巴结转移的危险因素单因素分析发现:与肿瘤大小(P=0.016)、双侧肿瘤(P=0.010)、多灶性肿瘤(P=0.006)、包膜浸润(P=0.024)、BRAF基因突变(P=0.008)相关。淋巴结转移相关因素变量纳入Logistic多因素回归分析发现:与肿瘤大小(OR=2.674, 95%CI=1.702~3.997)、肿瘤多灶性(OR=1.371,95%CI=1.065~2.087)、包膜浸润(OR=0.540,95%CI=0.396~0.794)、BRAF 突变(OR=1.647,95%CI=1.101~2.463)具有相关性,为cN0期PTC淋巴结转移的危险因素。结论: 临床检查、B超术前检查及术中探查无淋巴结转移的N0期PTC患者隐性淋巴结转移发生率为36.11%,BRAF基因突变、肿瘤大小、多灶性、包膜侵犯可能是预测中央区颈部淋巴结转移的危险因素,有中央区淋巴结转移危险因素者应选择性预防性中央区淋巴结清扫。
- 甲状腺乳头状癌 /
- BRAF基因突变 /
- 中央区淋巴结转移 /
- 中央区淋巴结清扫
Abstract: Objective: To study the prevalence of BRAF^V600E mutations in small (≤ 2 cm) papillary thyroid carcinoma (PTC), explore the correlation with occult central nodal metastasis (CNM) of clinically-nodal negative (cN0) neck for small (≤ 2 cm) papillary thyroid carcinoma (PTC).Method: Primary tumor tissue (paraffin-embedded) from 72 patients with small (≤ 2 cm) cN0 PTC who underwent prophylactic central neck dissection (pCND) was tested for BRAF mutation. by nested PCR, the factors of lymph node metastasis such as clinicopathologic including tumor size, multifocality, extrathyroidal invasion, and BRAF mutations were analyzed. Prediction scores were generated using logistic regression models and BRAF was evaluated to see if it was a risk factor for CNM.Result: The prevalence of BRAF was 47.22%(34/72) while the rate of CNM was 36.11% (26/72). Univariate analysis showed that the risk factors of lymph node metastasis for cN0 PTC were significantly correlated with tumor size (P=0.016), bilateral tumor (P=0.010), multifocality (P=0.026), extrathyroidal invasion (P=0.024), and BRAF mutations (P=0.041). Univariate analysis showed that tumor size (OR=2.674, 95%CI=1.702-3.997),multifocality (OR=1.371,95% CI=1.065-2.087),extrathyroidal invasion (OR=0.540, 95%CI=0.396-0.794)and BRAF (OR=1.647,95%CI=1.101-2.463) were risk predictors of CNM.Conclusion: The incidence of central neck micrometastatic disease is 36.11% in patients with PTC deemed N0 preoperatively by clinical examination and ultrasound of the neck lymph nodes and intraoperatively by inspection of the central compartment. The factors of high risk of CNM included tumor size, multifocality, extrathyroidal invasion, BRAF mutations. When a patient has the risk factors of lymph node metastasis should be electived prophylactic CCND.
- papillary thyroid carcinoma /
- BRAF mutation /
- central nodal metastasis /
- central neck dissection

HTML全文

参考文献(23)

[1]	SHAHA A R. Implications of prognostic factors and risk groups in the management of differentiated thyroid cancer[J]. Laryngoscope, 2004,114:393-402.
[2]	CARON N R, CLARK O H. Papillary thyroid cancer:surgical management of lymph node metastases[J]. Curr Treat Options Oncol, 2005,6:311-322.
[3]	高庆军,王南鹏,周彦,等.甲状腺乳头状癌颈部淋巴结转移规律及影响因素分析[J].中国普外基础与临床杂志, 2013,20(3):303-309.
[4]	MOO T A, MCGILL J, ALLENDORF J, et al. Impact of prophylactic central neck lymph node dissection on early recurrence in papillary thyroid carcinoma[J]. World J Surg, 2010,34:1187-1191.
[5]	FRASCA F, NUCERA C, PELLEGRITI G, et al. BRAF (V600E) mutation and the biology of papillary thyroid cancer[J]. Endocr Relat Cancer, 2008,15:191-205.
[6]	TUFANO R P, TEIXEIRA G V, BISHOP J, et al. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment:a systematic review and meta-analysis[J]. Medicine (Baltimore), 2012,91:274-286.
[7]	滕卫平,刘永锋,高明,等.甲状腺结节和分化型甲状腺癌诊治指南[J].中国肿瘤临床, 2012,39(17):1249-1272.
[8]	THE ATASURGERY WORKING GROUP. Consensus statement on the terminology and classificication of central neck dissection for thyroid cancer[J]. Thyroid, 2009,19:1153-1158.
[9]	LANG B H, NG S H, LAU L L, et al. A systematic review and meta-analysis of prophylactic central neck dissection on short-term locoregional recurrence in papillary thyroid carcinoma after total thyroidectomy[J]. Thyroid, 2013,23:1087-1098.
[10]	李森朋,张岫美,张芮. BRAF基因突变与肿瘤耐药[J].药学研究, 2013,32(8):470-472.
[11]	MATHUR A, MOSES W, RAHBARI R, et al. Higher rate of BRAF mutation in papillary thyroid cancer over time:a single-institution study[J]. Cancer, 2011,117:4390-4395.
[12]	KONDO T, EZZAT S, ASA S L. Pathogenetic mechanisms in thyroid follicular-cell neoplasia[J]. Nat Rev Cancer, 2006,6:292-306.
[13]	石光清,曹艳. Survivin蛋白和BRAF基因在甲状腺癌中的表达[J].中国现代医学杂志, 2012,22(19):61-66.
[14]	KIM S W, LEE J L,KIM J W,et al. BRAF V600E mutation analysis in fine-needle aspiration cytology specimens for evaluation of thyroid nodule:a large series in a BRAF V600E-prevalent population[J]. J Clin Endocrinol Metab, 2010,95:3693-3700.
[15]	KIM S J,LEE K E, MYONG J P, et al. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer[J]. World J Surg, 2012,36:310-317.
[16]	XING M,ALZAHRANI A S,CARSON K A,et al.Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer[J]. JAMA, 2013,309:1493-1501.
[17]	ELISEI R,UGOLINI C,VIOLA D,et al. BRAF^V600E mutation and out-come of patients with papillary thyroid carcinoma:a 15-year median follow-up study[J]. J Clin Endocrinol Metab, 2008,93:3943-3949.
[18]	XING M, WESTRA W H, TUFANO R P, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer[J]. J Clin Endocrinol Metab, 2005,90:6373-6379.
[19]	黄伟,吴高松.甲状腺癌相关BRAF基因研究的新进展[J].中国普通外科杂志, 2010,19(5):559-563.
[20]	MANTINAN B, REGO-IRAETA A, LARRANAGA A,et al. Factors influencing the outcome of patients with incidental papillary thyroid microcarcinoma[J]. J of Thyroid Res, 2012,2012:469397.
[21]	ZHAO Y, ZHANG Y, LIU X J, et al. Prognostic factors for differentiated thyroid carcinoma and review of the literature[J]. Tumori, 2012,98:233-237.
[22]	CHAKRABORTY A, NARKAR A, MUKHOPADHYAYA R, et al. BRAF V600E mutation in papillary thyroid carcinoma:significant association with node metastases and extra thyroidal invasion[J]. Endocr Pathol, 2012,23:83-93.
[23]	CHENG S, SERRA S, MERCADO M, et al. A high-throughput proteomic approach provides distinct signatures for thyroid cancer behavior[J]. Clin Cancer Res, 2011, 17:2385-2394.